{"title":"Section 2: Diagnosis and Classification of Diabetes","authors":"","doi":"10.2337/cd24-a002","DOIUrl":"https://doi.org/10.2337/cd24-a002","url":null,"abstract":"","PeriodicalId":519493,"journal":{"name":"Clinical Diabetes : A Publication of the American Diabetes Association","volume":"118 ","pages":"183 - 185"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140797662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Imeglimin.","authors":"Megan Giruzzi","doi":"10.2337/cd21-0085","DOIUrl":"https://doi.org/10.2337/cd21-0085","url":null,"abstract":"Glycemic control for type 2 diabetes continues to be a global concern, with diabetes entering the top 10 causes of death globally, at number nine, in 2020 (1). Studies have found that glycemic control has declined in the last several years, with <60% of patients meeting their A1C goal in 2014 (2). A more recent review found that young adults with type 2 diabetes have worse glycemic control than past cohorts, with an average A1C of 8.5% (3). There are many challenges to the management of diabetes, including high health care costs, poor patient adherence, and contraindications to and side effect profiles of available drug classes that limit their use.","PeriodicalId":519493,"journal":{"name":"Clinical Diabetes : A Publication of the American Diabetes Association","volume":"39 4","pages":"439-440"},"PeriodicalIF":0.0,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8603315/pdf/diaclincd210085.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39694268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Telehealth to Avoid Emergency Department Visit and Hospitalization for a Person With Newly Diagnosed Type 1 Diabetes During the Coronavirus Disease 2019 Pandemic.","authors":"Anthony J Pick, Monica Joyce","doi":"10.2337/cd21-0007","DOIUrl":"https://doi.org/10.2337/cd21-0007","url":null,"abstract":"a vital signs and physical examination normal, but point-of-care glucose levels were in the 300-mg/dL range, with urine positive for glucose and ketones. re-ports","PeriodicalId":519493,"journal":{"name":"Clinical Diabetes : A Publication of the American Diabetes Association","volume":"39 4","pages":"445-448"},"PeriodicalIF":0.0,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8603324/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39694270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The Clinical Definition of Overbasalization.","authors":"Mayer B Davidson","doi":"10.2337/cd21-0025","DOIUrl":"https://doi.org/10.2337/cd21-0025","url":null,"abstract":"","PeriodicalId":519493,"journal":{"name":"Clinical Diabetes : A Publication of the American Diabetes Association","volume":"39 4","pages":"411-414"},"PeriodicalIF":0.0,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8603322/pdf/diaclincd210025.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39694263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Ultra-Rapid-Acting Insulins: How Fast Is Really Needed?","authors":"Eva Y Wong, Lisa Kroon","doi":"10.2337/cd20-0119","DOIUrl":"https://doi.org/10.2337/cd20-0119","url":null,"abstract":"<p><strong>Objective: </strong>To review the new ultra-rapid-acting insulin analogs and describe the benefits and limitations compared with other bolus insulins.</p><p><strong>Summary: </strong>The options for bolus insulins, which are usually taken at mealtime or for correction of hyperglycemia, are expanding, with recent approvals of faster-acting insulin aspart and insulin lispro-aabc. These new-generation insulins contain additives that enhance absorption and accelerate onset of action. Clinical studies demonstrate that, although these insulins are faster acting, their efficacy for A1C lowering and safety in terms of hypoglycemia risk are similar to those of other available bolus insulin options such as rapid-acting insulin analogs. However, their use resulted in significant reductions in 1- and 2-hour postprandial glucose levels.</p><p><strong>Conclusion: </strong>Novel ultra-rapid-acting insulins provide additional bolus insulin options, and their quick onset of action provides additional dosing flexibility for people with diabetes. Given their comparable efficacy and safety compared to other quick-acting insulins, health care providers should engage in shared decision-making with patients and their caregivers regarding possible use of ultra-rapid-acting insulin, taking into account their preferences, individualized considerations, and insurance formulary coverage. These new insulin formulations may be a suitable option for people with diabetes who are not able to achieve postprandial glycemic targets with other bolus insulins.</p>","PeriodicalId":519493,"journal":{"name":"Clinical Diabetes : A Publication of the American Diabetes Association","volume":"39 4","pages":"415-423"},"PeriodicalIF":0.0,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8603316/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39694264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Wendy Lane, Emma Lambert, Jesso George, Naveen Rathor, Nandu Thalange
{"title":"Exploring the Burden of Mealtime Insulin Dosing in Adults and Children With Type 1 Diabetes.","authors":"Wendy Lane, Emma Lambert, Jesso George, Naveen Rathor, Nandu Thalange","doi":"10.2337/cd20-0117","DOIUrl":"https://doi.org/10.2337/cd20-0117","url":null,"abstract":"<p><p>Timely and accurate mealtime insulin dosing can be an ongoing challenge for people with type 1 diabetes. This multinational, online study aimed to explore attitudes and behaviors around mealtime insulin dosing and the impact of mealtime dose timing, particularly with regard to premeal dosing (15-20 minutes before a meal). Although the majority of surveyed participants (96%) recognized the importance of accurate mealtime bolus insulin dosing, only a small proportion (35%) reported being \"very confident\" in accurate bolus insulin estimation. Given the choice, the majority of participants would prefer to administer insulin immediately before or after a meal, as this timing would improve their quality of life.</p>","PeriodicalId":519493,"journal":{"name":"Clinical Diabetes : A Publication of the American Diabetes Association","volume":"39 4","pages":"347-357"},"PeriodicalIF":0.0,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8603317/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39692931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Good to Know: Peripheral Arterial Disease.","authors":"","doi":"10.2337/cd21-pe04","DOIUrl":"https://doi.org/10.2337/cd21-pe04","url":null,"abstract":"<p><p>Peripheral arterial disease, also called PAD, happens when blood vessels in your legs are narrowed or blocked by fatty deposits. Blood flow to your feet and legs decreases, causing pain and circulation problems. When blood flow is reduced, your muscles can't get enough oxygen.</p>","PeriodicalId":519493,"journal":{"name":"Clinical Diabetes : A Publication of the American Diabetes Association","volume":"39 4","pages":"437-438"},"PeriodicalIF":0.0,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8603321/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39694267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Metformin Extended-Release Oral Solution.","authors":"Laura Elizabeth Satterwhite","doi":"10.2337/cd21-0009","DOIUrl":"https://doi.org/10.2337/cd21-0009","url":null,"abstract":"Metformin hydrochloride extended-release oral suspension (Riomet ER) is a reformulation of a biguanide that was approved by the U.S. Food and Drug Administration on 29 August 2019 for the treatment of type 2 diabetes (1). The American Diabetes Association’s Standards of Medical Care in Diabetes—2021 recommends metformin as the preferred initial pharmacological agent for treatment of type 2 diabetes (2). These guidelines also recommend that, once initiated, metformin should be continued as tolerated.","PeriodicalId":519493,"journal":{"name":"Clinical Diabetes : A Publication of the American Diabetes Association","volume":"39 2","pages":"226-227"},"PeriodicalIF":0.0,"publicationDate":"2021-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8061547/pdf/diaclincd210009.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38980498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jeoffrey A Bispham, Allyson S Hughes, Ludi Fan, Magaly Perez-Nieves, Alicia H McAuliffe-Fogarty
{"title":"\"I've Had an Alarm Set for 3:00 a.m. for Decades\": The Impact of Type 1 Diabetes on Sleep.","authors":"Jeoffrey A Bispham, Allyson S Hughes, Ludi Fan, Magaly Perez-Nieves, Alicia H McAuliffe-Fogarty","doi":"10.2337/cd20-0026","DOIUrl":"https://doi.org/10.2337/cd20-0026","url":null,"abstract":"<p><p>There is a dearth of research characterizing the impact on a caregiver's sleep when caring for a minor with type 1 diabetes. This study used focus groups of people with type 1 diabetes and caregivers of minors with type 1 diabetes to explore the experience of how diabetes affects sleep. The occurrence of both unanticipated and planned sleep disruptions led to the majority of participants reporting that their sleep was considerably affected by diabetes. Despite the improvement in blood glucose management that diabetes technology devices can provide, people with type 1 diabetes and their caregivers still report sleep disruption and sleep loss resulting from overnight diabetes management.</p>","PeriodicalId":519493,"journal":{"name":"Clinical Diabetes : A Publication of the American Diabetes Association","volume":"39 2","pages":"153-159"},"PeriodicalIF":0.0,"publicationDate":"2021-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8061550/pdf/diaclincd200026.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38991494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Suggestions to Overcome Racial Inequities Among Health Care Professionals.","authors":"Joy A Dugan-Moverley","doi":"10.2337/cd20-0070","DOIUrl":"https://doi.org/10.2337/cd20-0070","url":null,"abstract":"","PeriodicalId":519493,"journal":{"name":"Clinical Diabetes : A Publication of the American Diabetes Association","volume":"39 2","pages":"197-198"},"PeriodicalIF":0.0,"publicationDate":"2021-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8061537/pdf/diaclincd200070.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38991497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}